Group 1 - Company Lijiang Co., Ltd. reported a revenue of approximately 660 million yuan for the first three quarters of 2025, representing a year-on-year increase of 3.79% [1] - The net profit attributable to shareholders of the listed company was approximately 192 million yuan, showing a slight decrease of 0.18% year-on-year [1] - Basic earnings per share were 0.3493 yuan, which is a decrease of 0.17% compared to the previous year [1] Group 2 - The market capitalization of Lijiang Co., Ltd. is currently 4.7 billion yuan [2]

Financial Performance - The company's operating revenue for Q3 2025 reached ¥282,022,008.75, representing a year-on-year increase of 12.44%[5] - Net profit attributable to shareholders was ¥97,424,334.35, up 21.83% compared to the same period last year[5] - The basic earnings per share (EPS) increased by 21.86% to ¥0.1773[5] - Total operating revenue for the current period reached ¥659,725,503.89, an increase of 3.4% compared to ¥635,646,072.63 in the previous period[23] - Operating profit for the current period was ¥265,903,148.10, slightly up from ¥262,981,866.09 in the previous period, reflecting a growth of 1.1%[24] - Net profit attributable to shareholders of the parent company was ¥191,926,567.20, a decrease of 0.2% from ¥192,276,433.52 in the previous period[24] - The basic and diluted earnings per share were both reported at ¥0.3493, slightly down from ¥0.3499 in the previous period[24] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥3,121,634,651.33, reflecting a 3.49% increase from the end of the previous year[5] - The total current liabilities decreased to ¥312,439,257.50 from ¥338,549,751.53, a reduction of approximately 7.7%[21] - The total liabilities decreased to ¥337,817,526.00 from ¥352,375,347.71, indicating a reduction of approximately 4.1%[22] - Total equity attributable to shareholders of the parent company increased to ¥2,537,497,346.47 from ¥2,527,687,099.80, reflecting a growth of 0.4%[22] - The non-current assets total is ¥2,185,875,179.44, up from ¥2,154,325,975.25, indicating an increase of about 1.5%[21] Cash Flow - The cash flow from operating activities for the year-to-date reached ¥315,224,876.06, an increase of 13.80% year-on-year[5] - Cash flow from operating activities generated a net amount of ¥315,224,876.06, an increase of 13.7% compared to ¥276,990,122.85 in the previous period[26] - The company received cash inflow from financing activities amounting to ¥78,533,944.78, a significant increase from ¥4,247,353.00 in the previous period[26] - Net cash flow from financing activities was -$144.19 million, compared to -$215.11 million in the previous period, indicating an improvement of approximately 33%[27] - The total cash outflow from financing activities amounted to $222.72 million, slightly up from $219.36 million year-over-year[27] - The net increase in cash and cash equivalents was -$248.01 million, contrasting with a positive increase of $116.85 million in the prior year[27] - The ending balance of cash and cash equivalents stood at $495.14 million, down from $739.31 million year-over-year, reflecting a decrease of approximately 33%[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 42,150[18] - The largest shareholder, Lijiang Yulong Snow Mountain Tourism Development Co., Ltd., holds 15.73% of shares, totaling 86,438,390 shares[18] - The company has not disclosed any related party relationships among the top shareholders beyond the known associations[18] Investments and Projects - The company reported a significant increase in construction in progress, which rose by 253.81% to ¥79,212,400, primarily due to the expansion of the Yak Cow Slope cableway project[8] - The company is in the process of installing imported cableway equipment, with the first batch arriving on October 20, 2025[19] - The company has completed the bidding for project design services and cost consulting for the renovation and expansion of the Yulong Snow Mountain cableway project[19] Accounts Receivable - The balance of accounts receivable increased by 91.45% to ¥8,861,900, attributed to higher ticket sales to travel agencies[8] - Accounts receivable increased to ¥18,552,077.20 from ¥9,690,132.77, representing an increase of approximately 91.5%[20] Tax and Investment Activities - The company experienced a 100% increase in tax refunds received, amounting to ¥16,623,100, due to the collection of retained tax refunds[14] - Investment payments surged by 1,787.18% to ¥349,000,000, driven by increased purchases of government bond reverse repos and low-risk bank financial products[14] Audit Status - The company’s third-quarter financial report was not audited, which may impact the reliability of the reported figures[28]

丽江玉龙旅游股份有限公司 信息披露暂缓与豁免业务管理制度 第一章 总则 第一条 为规范丽江玉龙旅游股份有限公司（以下简称"公司"）及相关信息披露义 务人信息披露暂缓、豁免行为，督促公司及相关信息披露义务人（以下简称"信息披露义 务人"）依法合规地履行信息披露义务，根据《中华人民共和国证券法》（以下简称"《证 券法》"）、《深圳证券交易所股票上市规则》（以下简称"《上市规则》"）、《上市公司信息披 露暂缓与豁免管理规定》（以下简称"《管理规定》"）、公司《信息披露制度》和其他有关 规定，制定本制度。 第二条 信息披露义务人暂缓、豁免披露临时报告，在定期报告、临时报告中豁免披 露中国证券监督管理委员会（以下简称"中国证监会"）和深圳证券交易所规定或者要求 披露的内容，适用本制度。 第三条 信息披露义务人应当披露的信息存在《管理规定》及深圳证券交易所其他相 关业务规则中规定的可暂缓、豁免信息披露的情形的，可以无须向深圳证券交易所申请， 由信息披露义务人自行审慎判断，并接受深圳证券交易所对有关信息披露暂缓、豁免事宜 的事后监管。 第二章 暂缓、豁免披露信息的范围 属于核心技术信息等，披露后可能引致不正当竞争的；（二） ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 丽江玉龙旅游股份有限公司(以下简称"公司")第七届董事会第四十一次会 议于 2025 年 10 月 24 日以传真通讯方式召开，公司已于 2025 年 10 月 19 日以通 讯方式发出会议通知，会议应出席董事 11 名，实际出席董事 11 名，会议的召集、 召开符合《公司法》和《公司章程》的规定，本次会议以通讯表决方式通过了以 下议案： 1、审议通过《关于<公司 2025 年第三季度报告>的议案》 《公司 2025 年第三季度报告》登载于《证券时报》、《中国证券报》及巨潮 资讯网（http://www.cninfo.com.cn）。 证券代码：002033 证券简称：丽江股份 公告编号：2025030 丽江玉龙旅游股份有限公司 第七届董事会第四十一次会议决议公告 《 公 司 信 息 披 露 暂 缓 与 豁 免 业 务 管 理 制 度 》 登 载 于 巨 潮 资 讯 网 （http://www.cninfo.com.cn）。 表决结果：11 票赞成、0 票反对、0 票弃权 特此公告。 丽江玉龙旅游股份有限公司董事 ...

Core Insights - Huabang Health, established in 1992, is a leading enterprise in the field of clinical skin medications and skin health in China [1] - The company has developed a diversified business model focusing on the health industry, with independent operations in agricultural chemicals, new materials, and tourism [1] - Huabang Health's business scope includes five major areas: pharmaceuticals, medical services, agricultural chemicals, new materials, and tourism [1] Business Structure - The company controls three listed subsidiaries: Yingtai Biotechnology (920819.BJ), Kaisheng New Materials (301069.SZ), and Lijiang Co. (002033.SZ) [1] - It also holds a controlling stake in a New Third Board enterprise, Qinling Tourism (870256.NQ), and has a stake in another New Third Board company, Purikin (874090.NQ) [1] Future Strategy - The company plans to adhere to its development strategy in pharmaceuticals and medical health, continuously improving its full industry chain model that integrates raw materials, formulations, functional skincare products, comprehensive skin health management, and medical services [1] - Huabang Health aims to maintain the independent and stable operation of its three listed companies while leveraging its role as a controlling shareholder in governance [1]

Core Insights - The article discusses the rising popularity and profitability of cable cars in tourist destinations, highlighting their role as a significant revenue source for various listed companies in the tourism sector [1][3][5]. Industry Overview - The cable car business has become a "cash cow" for many scenic spots, with profit margins reaching up to 80% [1]. - The average ticket prices for cable cars can be quite high, with some prices nearing or exceeding entrance fees, such as the Huashan West Peak cable car priced at 140 yuan per person, close to the 160 yuan entrance fee [1]. - Major listed companies in the A-share market, such as Huangshan Tourism, SanTe Cableway, and Lijiang Co., report significant revenues from their cable car operations, with Huangshan Tourism's cable car revenue reaching 718 million yuan [3][5]. Financial Performance - The cable car business often has higher gross profit margins compared to other segments, with Huangshan's cable car business achieving a gross margin of 87.56% [5]. - For example, the gross margin for Emei Mountain A's cable car business is 83.88%, while other segments like hotel services have much lower margins [5]. - The revenue from cable cars constitutes a substantial portion of total revenues for companies, with SanTe Cableway's cable car revenue accounting for 79.6% of its total income [3][5]. Market Dynamics - The cable car market is characterized by relatively few competitors, leading to better profit margins due to its monopolistic nature [6]. - The increasing number of cable cars in China, nearly 900, reflects their growing importance in enhancing tourist experiences [6]. - The demand for cable cars is driven by the need for convenience and the immersive experience they provide, especially among younger tourists [6]. Customer Sentiment - Visitor reviews indicate a generally positive sentiment towards cable cars, with convenience and scenic views being highlighted as key benefits [13][15]. - However, there are notable negative sentiments regarding high prices and operational inefficiencies, particularly during peak seasons, leading to long wait times and customer dissatisfaction [17][18][19].

Company Overview - Founded in 1992, Huabang Life Health Co., Ltd. is a leading enterprise in the field of dermatological clinical medications and health [1] - The company operates in five major sectors: pharmaceuticals, medical services, agricultural chemicals, new materials, and tourism, with three listed subsidiaries [1] - Future strategy focuses on the development of a comprehensive health industry chain, integrating raw materials, formulations, functional skincare products, and medical services [1] Pharmaceutical Business - The pharmaceutical segment is stable, focusing on the R&D, production, and sales of pharmaceutical formulations and active pharmaceutical ingredients (APIs) [3] - The product matrix includes treatments for common skin conditions such as dermatitis, eczema, allergies, acne, and psoriasis, catering to all age groups [3][4] - The company has three major API production bases, ensuring a steady supply of core products and establishing long-term partnerships with international pharmaceutical companies [3] Impact of Drug Procurement Policies - The impact of national drug procurement policies on the company is currently limited due to the slower inclusion of dermatological medications in procurement [6] - The company is actively working on the consistency evaluation of generic drugs and controlling production costs to prepare for future procurement participation [6] - A comprehensive product matrix in dermatology allows the company to mitigate risks associated with procurement by promoting alternative products [6] Medical Services - The company has developed a layered business ecosystem that includes basic medicine, rehabilitation medicine, and health management services [7] - Facilities like Chongqing Songshan Hospital focus on basic medical treatment, while others specialize in rehabilitation and health management [7] Dividend Policy - The company has maintained a high dividend payout policy, distributing approximately 3 billion CNY since 2018 [9] - Plans to sustain a high dividend basis and explore diversified distribution methods in the future [9] Shareholding in Pruijin - The company holds a total of 13.2% equity in Pruijin, making it the third-largest shareholder [10] Collaboration with KITE Pharma - Pruijin has entered a global collaboration with KITE Pharma for in vivo editing therapies, receiving an upfront payment of 120 million USD and potential milestone payments totaling up to 1.52 billion USD [11] Advantages of In Vivo CAR-T Technology - In vivo CAR-T technology simplifies treatment by eliminating complex steps, reducing costs, and allowing for large-scale production [12]

Core Insights - The tourism and scenic spots sector increased by 2.78% on October 20, with Dalian Shengya leading the gains [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] Sector Performance - Dalian Shengya (600593) closed at 41.78, up 10.01% with a trading volume of 138,700 shares [1] - Changzi Mountain (660E09) closed at 51.88, up 8.81% with a trading volume of 251,600 shares [1] - Caesar Travel (000796) closed at 6.68, up 7.05% with a trading volume of 2,334,700 shares [1] - Tianfu Cultural Tourism (000558) closed at 5.39, up 4.46% with a trading volume of 771,900 shares [1] - Other notable performers include Tibet Tourism (600749) up 3.08% and Xiyu Tourism (300859) up 2.69% [1] Capital Flow - The tourism and scenic spots sector saw a net inflow of 442 million yuan from main funds, while retail investors experienced a net outflow of 245 million yuan [2] - The main funds' net inflow for Caesar Travel was 171 million yuan, representing 10.87% of its trading volume [3] - Changzi Mountain also saw a significant net inflow of 123 million yuan, accounting for 9.60% of its trading volume [3]

Market Overview - The tourism and scenic spots sector rose by 0.45% on October 14, with Dalian Shengya leading the gains [1] - The Shanghai Composite Index closed at 3865.23, down 0.62%, while the Shenzhen Component Index closed at 12895.11, down 2.54% [1] Stock Performance - Dalian Shengya (600593) closed at 36.18, up 5.21% with a trading volume of 78,300 shares and a turnover of 281 million yuan [1] - Other notable gainers include Changzi Mountain (6638209) up 2.97% and Caesar Travel (000796) up 2.42% [1] - Conversely, several stocks in the sector experienced declines, with Xi'an Tourism (000610) down 0.66% and ST Zhangjiajie (000430) down 0.65% [2] Capital Flow - The tourism and scenic spots sector saw a net outflow of 43.63 million yuan from institutional investors and 57.86 million yuan from speculative funds, while retail investors had a net inflow of 101 million yuan [2] - The capital flow data indicates that major stocks like Caesar Travel and Changzi Mountain experienced mixed capital movements, with Caesar Travel seeing a net inflow of 38.39 million yuan from institutional investors [3] Detailed Stock Data - The table of stock performance shows various companies with their closing prices, percentage changes, trading volumes, and turnover amounts, highlighting the overall market dynamics within the tourism sector [1][2] - Notable stocks with significant trading activity include Caesar Travel with a turnover of 60.2 million yuan and Changzi Mountain with 600 million yuan [1][2]

Core Viewpoint - Lijiang Co., Ltd. is actively developing its IP economy, leveraging its natural and cultural assets to enhance tourism experiences and drive growth [2]. Group 1: Company Performance - As of October 13, 2025, Lijiang Co., Ltd. closed at 8.45 yuan, down 1.05%, with a turnover rate of 2.62%, a trading volume of 144,000 shares, and a transaction value of 121 million yuan [1]. - The company reported a net outflow of 9.7463 million yuan from main funds on October 13, indicating a trend of capital withdrawal [3]. Group 2: IP Economy Development - The company has established a dual IP framework, focusing on "Yulong Snow Mountain" as a natural IP and "Impression Lijiang" as a cultural IP, which are key to its branding and tourism strategy [2]. - Lijiang Co., Ltd. is expanding its offerings around these IPs, including tourism cable cars, dining, cultural products, and high-end resorts, to enhance visitor experiences and capitalize on its unique resources [2]. Group 3: Upcoming Financial Disclosure - The company plans to release its third-quarter report on October 25, 2025, with normal business operations reported for the third quarter [2].